Hostname: page-component-89b8bd64d-7zcd7 Total loading time: 0 Render date: 2026-05-07T19:30:52.173Z Has data issue: false hasContentIssue false

What makes the psychosis ‘clinical high risk’ state risky: psychosis itself or the co-presence of a non-psychotic disorder?

Published online by Cambridge University Press:  06 July 2021

Laila Hasmi
Affiliation:
Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, the Netherlands
Lotta-Katrin Pries
Affiliation:
Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, the Netherlands
Margreet ten Have
Affiliation:
Department of Epidemiology, Netherlands Institute of Mental Health and Addiction, Utrecht, The Netherlands
Ron de Graaf
Affiliation:
Department of Epidemiology, Netherlands Institute of Mental Health and Addiction, Utrecht, The Netherlands
Saskia van Dorsselaer
Affiliation:
Department of Epidemiology, Netherlands Institute of Mental Health and Addiction, Utrecht, The Netherlands
Maarten Bak
Affiliation:
Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, the Netherlands FACT, Mondriaan Mental Health, Maastricht, Netherlands
Gunter Kenis
Affiliation:
Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, the Netherlands
Alexander Richards
Affiliation:
MRC Centre for Neuropsychiatric Genetics & Genomics, Division of Psychological Medicine & Clinical Neurosciences, Cardiff University, Cardiff, United Kingdom
Bochao D. Lin
Affiliation:
Department of Translational Neuroscience, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands Department of Neurology, Brain Centre Rudolf Magnus, University Medical Centre Utrecht, Utrecht, the Netherlands
Michael C. O'Donovan
Affiliation:
MRC Centre for Neuropsychiatric Genetics & Genomics, Division of Psychological Medicine & Clinical Neurosciences, Cardiff University, Cardiff, United Kingdom
Jurjen J. Luykx
Affiliation:
Department of Translational Neuroscience, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands GGNet Mental Health, Apeldoorn, The Netherlands Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
Bart P.F. Rutten
Affiliation:
Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, the Netherlands
Sinan Guloksuz
Affiliation:
Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, the Netherlands Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
Jim van Os*
Affiliation:
Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, the Netherlands Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
*
Author for correspondence: Jim van Os, E-mail: j.j.vanos-2@umcutrecht.nl
Rights & Permissions [Opens in a new window]

Abstract

Aims

Although attenuated psychotic symptoms in the psychosis clinical high-risk state (CHR-P) almost always occur in the context of a non-psychotic disorder (NPD), NPD is considered an undesired ‘comorbidity’ epiphenomenon rather than an integral part of CHR-P itself. Prospective work, however, indicates that much more of the clinical psychosis incidence is attributable to prior mood and drug use disorders than to psychosis clinical high-risk states per se. In order to examine this conundrum, we analysed to what degree the ‘risk’ in CHR-P is indexed by co-present NPD rather than attenuated psychosis per se.

Methods

We examined the incidence of early psychotic experiences (PE) with and without NPD (mood disorders, anxiety disorders, alcohol/drug use disorders), in a prospective general population cohort (n = 6123 at risk of incident PE at baseline). Four interview waves were conducted between 2007 and 2018 (NEMESIS-2). The incidence of PE, alone (PE-only) or with NPD (PE + NPD) was calculated, as were differential associations with schizophrenia polygenic risk score (PRS-Sz), environmental, demographical, clinical and cognitive factors.

Results

The incidence of PE + NPD (0.37%) was lower than the incidence of PE-only (1.04%), representing around a third of the total yearly incidence of PE. Incident PE + NPD was, in comparison with PE-only, differentially characterised by poor functioning, environmental risks, PRS-Sz, positive family history, prescription of antipsychotic medication and (mental) health service use.

Conclusions

The risk in ‘clinical high risk’ states is mediated not by attenuated psychosis per se but specifically the combination of attenuated psychosis and NPD. CHR-P/APS research should be reconceptualised from a focus on attenuated psychotic symptoms with exclusion of non-psychotic DSM-disorders, as the ‘pure' representation of a supposedly homotypic psychosis risk state, towards a focus on poor-outcome NPDs, characterised by a degree of psychosis admixture, on the pathway to psychotic disorder outcomes.

Information

Type
Original Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
Copyright © The Author(s), 2021. Published by Cambridge University Press
Figure 0

Table 1. Incidence of PE, either alone or co-present with NPDs

Figure 1

Fig. 1. Hazard ratio (HR) effect sizes of binary clinical, demographic, aetiological and cognitive factors in PE-only group relative to effect sizes of PE + NPD group (set at 100%, grey line). Young age group: aged 18–35 years; Perceived status gap: difference between actual and desired social position; Low social functioning: SF36 social functioning 75th percentile cut-off; Any care: any informal, medical or mental health care for mental problems or addiction; Cannabis use: once per week or more in the period of most frequent use; Childhood adversity: 80th percentile cut-off continuous adversity score before age 16 years; Life events: at least one life event in the last year; Minority: Moroccan, Turkish, Surinamese, Antillean, Indonesian or other non-western ethnic group; Hearing impairment: T0 deafness or serious hearing impairment in the past 12 months; Urbanicity: 2 highest levels of 5-level urbanicity classification before age 16 years; Family history: family history mental disorder; PRS75: schizophrenia polygenic risk score 75th percentile cut-off; JTC: beads task decision 2 or less beads; Altered digit symbol: cut-off 75th percentile continuous score.

Figure 2

Table 2. Distribution of risk factors (proportions) as a function of PE, either alone or in combination with NPD across T0, T1, T2 and T3 repeated observations (6123 individuals yielding 19 115 observations)

Figure 3

Table 3. Differential associations of incident PE, alone (PE-only) and in the context of NPD (PE + NPD), with demographic, clinical, aetiological and cognitive factors

Supplementary material: File

Hasmi et al. supplementary material

Hasmi et al. supplementary material

Download Hasmi et al. supplementary material(File)
File 309.3 KB